EPO and chronic kidney disease: Considering therapy of anemia with erythropoietin may induce or worsen the occurrence of hypertension, and the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) conducted in predialysis patients with CKD stages 2, 3 or 4 and diabetes found no reduced risk of death in the ESAs treated group compared with placebo-controlled group, and treating anemia with ESAs maybe harmful [29], We divided the high and low Hb targets into another two subgroups based on whether or not the patients were given ESAs for anemia treatment, and the statistical analysis was also computed separately.